In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

HighLife brings in €32mm via Series B

Executive Summary

HighLife SAS (developing a transcatheter mitral valve replacement system for patients suffering from mitral regurgitation) raised €32mm ($36.6mm) in its Series B financing led by US Venture Partners and Andera Partners, which were joined by Sectoral Asset Management, Sofinnova Partners, and HighLife chairman Jose Calle Gordo. The company will use the funds to finish development of the transcatheter transseptal mitral valve implantation system, including regulatory approval trials in Europe necessary to obtain the CE mark and an early feasibility study in the US. Bryan Garnier & Co. was the placement agent.
Deal Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register